On October 6, 2026, Larry Robbins (Trades, Portfolio) of Glenview Capital Management initiated a new position in Surgery Partners Inc (SGRY), acquiring 7,023,33
On October 6, 2026, Larry Robbins (Trades, Portfolio) of Glenview Capital Management initiated a new position in Surgery Partners Inc (SGRY), acquiring 7,023,33
On October 6, 2026, Larry Robbins (Trades, Portfolio) of Glenview Capital Management initiated a new position in Surgery Partners Inc SGRY, acquiring 7,023,338 shares at a trade price of $13.41. This transaction establishes a fresh holding for the firm, representing 1.69% of the guru's portfolio and 5.40% of the company's outstanding shares. The move signals a notable vote of confidence in the healthcare services provider, particularly given the firm's existing concentration in the healthcare sector. As of the article date of October 15, 2026, the stock has risen 10.59% since the transaction, trading at $14.83. This new acquisition aligns with Glenview's strategy of deep fundamental research and individual security selection, suggesting the firm sees compelling value in Surgery Partners' business model and market positioning.
Guru Profile: Larry Robbins (Trades, Portfolio) and Glenview Capital Management
Glenview Capital Management, founded in 2000 by Larry Robbins (Trades, Portfolio), is a privately held investment management firm managing assets across two primary products: the Glenview Funds (long/short) and the Glenview Opportunity Funds (concentrated, opportunistic). The firm focuses on delivering attractive absolute returns through intense fundamental research and individual security selection, with investments primarily in the U.S. and a smaller exposure in Western Europe. As of the latest data, the firm manages equity of $5.49 billion across 45 stock holdings. The top sector concentrations are Healthcare and Industrials, with top holdings including Amazon.com Inc AMZN, CVS Health Corp CVS, Global Payments Inc GPN, Tenet Healthcare Corp THC, and Thermo Fisher Scientific Inc TMO. This sector alignment provides context for the new position in Surgery Partners, a healthcare services company.
Company Overview: Surgery Partners Inc SGRY
Surgery Partners Inc is a U.S. healthcare services company operating a network of surgical facilities, primarily ambulatory surgery centers (ASCs) and surgical hospitals, along with affiliated anesthesia services and multi-specialty physician practices. The company provides outpatient and short-stay surgical procedures across specialties such as orthopedics, ophthalmology, gastroenterology, pain management, and cardiology. Revenue is generated through patient care services reimbursed by Medicare, Medicaid, private insurers, and patients, as well as management and administrative fees from affiliated facilities. The business model emphasizes cost-effective, high-quality outpatient care as an alternative to traditional hospital-based surgery. Surgery Partners operates a single reporting segment, Surgical Facilities, through partnerships with physicians and health systems, often holding majority or joint-venture ownership stakes. The company has a market cap of $1.94 billion, a current stock price of $14.83, and went public on October 1, 2015.
Valuation and Financial Health Metrics
According to GuruFocus valuation metrics, Surgery Partners has a GF Value of $24.43, and with the current price of $14.83, the price-to-GF Value ratio stands at 0.61. This suggests the stock is potentially undervalued by approximately 39% relative to its intrinsic value estimate. However, the GF Valuation label carries a cautionary note: "Possible Value Trap, Think Twice." This designation indicates that despite the low price-to-GF Value ratio, investors should exercise prudence. The company's financial ranks further reflect mixed signals: Balance Sheet Rank of 3/10, Profitability Rank of 4/10, Growth Rank of 4/10, and a GF Score of 62/100. A GF Score in the 51-70 range suggests poor future performance potential, underscoring the need for careful analysis despite the apparent undervaluation.
Performance and Momentum Indicators
Since the transaction date of October 6, 2026, Surgery Partners stock has gained 10.59%, though year-to-date performance remains negative at -2.82%. The stock's IPO percent change since its 2015 listing stands at -15.5%. Momentum indicators present a mixed picture: the 5-day RSI is 80.35, signaling overbought conditions, while the 9-day and 14-day RSIs are 65.03 and 58.10, respectively. The Momentum Index for the 6-1 month period is 7.18, indicating positive recent momentum, but the 12-1 month Momentum Index is -32.92, reflecting longer-term weakness. These metrics suggest short-term strength but caution regarding sustainability, especially with the overbought RSI reading. Investors should monitor whether the recent price appreciation is supported by fundamental improvements or merely a technical rebound.
Averytin News Financial update.